These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 37492015)

  • 1. Access and real-world use patterns of esketamine nasal spray among patients with treatment-resistant depression covered by private or public insurance.
    Teeple A; Zhdanava M; Pilon D; Caron-Lapointe G; Lefebvre P; Joshi K
    Curr Med Res Opin; 2023 Aug; 39(8):1167-1174. PubMed ID: 37492015
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Esketamine nasal spray for major depressive disorder with acute suicidal ideation or behavior: description of treatment access, utilization, and claims-based outcomes in the United States.
    Zhdanava M; Teeple A; Pilon D; Shah A; Caron-Lapointe G; Joshi K
    J Med Econ; 2023; 26(1):691-700. PubMed ID: 37130075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Understanding profiles of patients with treatment-resistant depression by stringency of health plan prior authorization criteria for approval of esketamine nasal spray.
    Harding L; Zhdanava M; Shah A; Pesa J; Totev TI; Tardif-Samson A; Pilon D; Joshi K
    Curr Med Res Opin; 2024 Sep; 40(9):1615-1623. PubMed ID: 39034772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characteristics of Real-world Commercially Insured Patients With Treatment-resistant Depression Initiated on Esketamine Nasal Spray or Conventional Therapies in the United States.
    Karkare S; Zhdanava M; Pilon D; Nash AI; Morrison L; Shah A; Lefebvre P; Joshi K
    Clin Ther; 2022 Nov; 44(11):1432-1448. PubMed ID: 36207167
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial.
    Daly EJ; Trivedi MH; Janik A; Li H; Zhang Y; Li X; Lane R; Lim P; Duca AR; Hough D; Thase ME; Zajecka J; Winokur A; Divacka I; Fagiolini A; Cubala WJ; Bitter I; Blier P; Shelton RC; Molero P; Manji H; Drevets WC; Singh JB
    JAMA Psychiatry; 2019 Sep; 76(9):893-903. PubMed ID: 31166571
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Esketamine Nasal Spray Plus Oral Antidepressant in Patients With Treatment-Resistant Depression: Assessment of Long-Term Safety in a Phase 3, Open-Label Study (SUSTAIN-2).
    Wajs E; Aluisio L; Holder R; Daly EJ; Lane R; Lim P; George JE; Morrison RL; Sanacora G; Young AH; Kasper S; Sulaiman AH; Li CT; Paik JW; Manji H; Hough D; Grunfeld J; Jeon HJ; Wilkinson ST; Drevets WC; Singh JB
    J Clin Psychiatry; 2020 Apr; 81(3):. PubMed ID: 32316080
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment Patterns, Acute Healthcare Resource Use, and Costs of Patients with Treatment-Resistant Depression Completing Induction Phase of Esketamine in the United States.
    Harding L; Joshi K; Zhdanava M; Shah A; Voegel A; Chen C; Pilon D
    Drugs Real World Outcomes; 2024 Jun; 11(2):209-219. PubMed ID: 38727888
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Esketamine nasal spray in patients with treatment-resistant depression: the real-world experience in the French cohort early-access programme.
    Samalin L; Rothärmel M; Mekaoui L; Gaudré-Wattinne E; Codet MA; Bouju S; Sauvaget A
    Int J Psychiatry Clin Pract; 2022 Nov; 26(4):352-362. PubMed ID: 35174754
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Practical recommendations for the management of treatment-resistant depression with esketamine nasal spray therapy: Basic science, evidence-based knowledge and expert guidance.
    Kasper S; Cubała WJ; Fagiolini A; Ramos-Quiroga JA; Souery D; Young AH
    World J Biol Psychiatry; 2021 Jul; 22(6):468-482. PubMed ID: 33138665
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment patterns, healthcare utilization, and costs of patients with treatment-resistant depression initiated on esketamine intranasal spray and covered by US commercial health plans.
    Joshi K; Pilon D; Shah A; Holiday C; Karkare S; Zhdanava M
    J Med Econ; 2023; 26(1):422-429. PubMed ID: 36924214
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Esketamine Nasal Spray on Olfactory Function and Nasal Tolerability in Patients with Treatment-Resistant Depression: Results from Four Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Studies.
    Doty RL; Popova V; Wylie C; Fedgchin M; Daly E; Janik A; Ochs-Ross R; Lane R; Lim P; Cooper K; Melkote R; Jamieson C; Singh J; Drevets WC
    CNS Drugs; 2021 Jul; 35(7):781-794. PubMed ID: 34235612
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Esketamine Nasal Spray versus Quetiapine for Treatment-Resistant Depression.
    Reif A; Bitter I; Buyze J; Cebulla K; Frey R; Fu DJ; Ito T; Kambarov Y; Llorca PM; Oliveira-Maia AJ; Messer T; Mulhern-Haughey S; Rive B; von Holt C; Young AH; Godinov Y;
    N Engl J Med; 2023 Oct; 389(14):1298-1309. PubMed ID: 37792613
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study.
    Popova V; Daly EJ; Trivedi M; Cooper K; Lane R; Lim P; Mazzucco C; Hough D; Thase ME; Shelton RC; Molero P; Vieta E; Bajbouj M; Manji H; Drevets WC; Singh JB
    Am J Psychiatry; 2019 Jun; 176(6):428-438. PubMed ID: 31109201
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Barriers to Esketamine Nasal Spray Treatment Among Adults With Treatment-Resistant Depression.
    Joshi K; Liberman JN; Parab P; Darer JD; Harding L
    J Clin Psychiatry; 2024 May; 85(2):. PubMed ID: 38722197
    [No Abstract]   [Full Text] [Related]  

  • 15. Efficacy and safety of fixed doses of intranasal Esketamine as an add-on therapy to Oral antidepressants in Japanese patients with treatment-resistant depression: a phase 2b randomized clinical study.
    Takahashi N; Yamada A; Shiraishi A; Shimizu H; Goto R; Tominaga Y
    BMC Psychiatry; 2021 Oct; 21(1):526. PubMed ID: 34696742
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and Safety of Esketamine Nasal Spray Plus an Oral Antidepressant in Elderly Patients With Treatment-Resistant Depression-TRANSFORM-3.
    Ochs-Ross R; Daly EJ; Zhang Y; Lane R; Lim P; Morrison RL; Hough D; Manji H; Drevets WC; Sanacora G; Steffens DC; Adler C; McShane R; Gaillard R; Wilkinson ST; Singh JB
    Am J Geriatr Psychiatry; 2020 Feb; 28(2):121-141. PubMed ID: 31734084
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term remission following esketamine nasal spray sessions in a patient with severe and highly treatment-resistant depression: a single-case report.
    Arrighi L; Maakaron E; Korchia T; Lançon C; Richieri R
    Int Clin Psychopharmacol; 2024 Sep; 39(5):323-325. PubMed ID: 37551607
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of esketamine nasal spray by sex in patients with treatment-resistant depression: findings from short-term randomized, controlled trials.
    Jones RR; Freeman MP; Kornstein SG; Cooper K; Daly EJ; Canuso CM; Nicholson S
    Arch Womens Ment Health; 2022 Apr; 25(2):313-326. PubMed ID: 34973081
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and tolerability of esketamine nasal spray versus quetiapine extended release in patients with treatment resistant depression.
    McIntyre RS; Bitter I; Buyze J; Fagiolini A; Godinov Y; Gorwood P; Ito T; Oliveira-Maia AJ; Vieta E; Werner-Kiechle T; Young AH; Reif A
    Eur Neuropsychopharmacol; 2024 Aug; 85():58-65. PubMed ID: 38954874
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiac Safety of Esketamine Nasal Spray in Treatment-Resistant Depression: Results from the Clinical Development Program.
    Doherty T; Wajs E; Melkote R; Miller J; Singh JB; Weber MA
    CNS Drugs; 2020 Mar; 34(3):299-310. PubMed ID: 31994024
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.